Fingerpaint acquired La Jolla, Calif.-based market access and commercialization firm 1798, and announced a new partnership with Thrive Global aimed at educating employees through personal health and wellness content and empowering them with the tools they need to improve productivity and manage stress.
W2O made three strategic acquisitions in October/November 2019 to expand the company’s capabilities. Now part of W2O are Arcus Medica; ISO.health; and Radius Digital Science.
As part of Fingerpaint’s continued commitment to bring forward the best opportunities to their clients, the full-service health and wellness marketing agency acquired 1798, a market access and commercialization firm located in La Jolla, Calif.
W2O acquired 21GRAMS – a rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human.
Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.
AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.
Internationally recognized healthcare marketing strategy firm 2e Creative joined the Fishawack Group after receiving investment from the global healthcare communications group.
David Lickrish – president, founder and chief executive officer of Highland Therapeutics and Ironshore Therapeutics – spoke with BioSpace about the companies’ Jornay PM (methylphenidate HCL Extended-Release CLL Capsules) and how the new drug fits into the overall ADHD therapeutic market.
Merck & Co. Inc. agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering the drugmaker‘s pipeline to treat cancer and autoimmune diseases.
